Discontinued — last reported Q3 '25
Viatris Cumulative Gross Losses and Impairments decreased by 67.8% to $124.00M in Q4 2023 compared to the prior quarter. Over 2 years (FY 2020 to FY 2023), Cumulative Gross Losses and Impairments shows a downward trend with a -43.2% CAGR. This is a positive signal — lower values indicate better performance for this metric.
An increase signals deteriorating value in the investment portfolio, potentially leading to future earnings charges.
This represents the total unrealized losses and impairment charges on investments that have not yet been reflected in ne...
Varies significantly based on the size and nature of a company's investment portfolio.
cumulative_gross_losses_and_impairments| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '23 | |
|---|---|---|---|---|---|---|---|
| Value | $385.00M | $385.00M | $385.00M | $385.00M | $385.00M | $385.00M | $124.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | -67.8% |
| YoY Change | — | — | — | — | +0.0% | +0.0% | — |
| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Developed Markets Segment | — | — | — | — | — | — | $3.19B | $3.19B |
| Japan, Australia and New Zealand Segment | $351.00M | $351.00M | $351.00M | $651.80M | $651.80M | $651.80M | $651.80M | $651.80M |
| Emerging Markets Segment | $124.00M | $124.00M | -$124.00M | $499.00M | $499.00M | $499.00M | $499.00M | $499.00M |
| Total | — | — | — | — | — | — | — | — |